Supplementary Figure 1 from GITR Pathway Activation Abrogates Tumor Immune Suppression Through Loss of Regulatory T-cell Lineage Stability

David A. Schaer,Sadna Budhu,Cailian Liu,Campbell Bryson,Nicole Malandro,Adam Cohen,Hong Zhong,Xia Yang,Alan N. Houghton,Taha Merghoub,Jedd D. Wolchok

DOI: https://doi.org/10.1158/2326-6066.22535846

2023-01-01

Abstract:PDF file - 143K, Foxp3 loss in Tregs is tumor and DTA-1 dose dependent

What problem does this paper attempt to address?

Supplemetal Data from Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Jin Zhang,Enshun Xu,Cong Ren,Hee Jung Yang,Yanhong Zhang,Wenqiang Sun,Xiangmudong Kong,Weici Zhang,Mingyi Chen,Eric Huang,Xinbin Chen

DOI: https://doi.org/10.1158/0008-5472.22417952

2023-01-01

Abstract:Supplemental Fig. S1 represents analysis of TLBL. Supplemental Fig. S2 contains representative images of H.E.-stained tumors. Supplemental Fig. S3 contains RT-PCR analysis of various genes (Tbet, NFAT1,NFAT2, IFNG, IL6) in thymus and TLBLs. Supplemental table S1-4 contains gender, survival, and tumor information of the mice.
GITR Costimulation Redirects Regulatory T Cells into Th9 Cells to Promote Antitumor Immunity (LYM8P.643)

Xiaomin Shi,Xiang Xiao,minhao wu,Yihui Fan,xiaolong zhang,chenglin wu,Rafik Ghobrial,Xian Li

DOI: https://doi.org/10.4049/jimmunol.194.supp.201.19

2015-01-01

The Journal of Immunology

Abstract:Abstract GITR is a potent T cell costimulatory molecule with diverse effects on effector and regulatory T cells, and because of this, GITR is of high potential for clinical development including anti-tumor immunity. However, the underlying mechanisms remain unclear. Here, we found that GITR ligation converted iTregs into Th9 cells in vitro. Mechanistically, GITR induced the sustained expression of p50 in activated CD4+ T cells, and p50 then recruited histone deacetylases HDAC1 and Sirt1 to the Foxp3 locus upon binding to the locus; this subsequently led to hypoacetylation, thus resulting in a closed epigenetic configuration of Foxp3 locus. Consistent with this, both p50-/- cells and treatment of HDAC inhibitor rescued iTregs from GITR-mediated suppression. We also found that Foxp3 is a potent repressor of IL-9, mainly through recruiting histone deacetylases to the IL-9 locus, and absence of Foxp3 rendered IL-9 locus accessible. In addition, p50 also promoted the expression of Th9 permissive transcription factors, including PU.1, Batf and Irf4, and all these factors together led to the induction of Th9 cells. Importantly, in a melanoma model in vivo, ligation of GITR using agonistic anti-GITR Ab blocked iTreg differentiation and inhibited tumor progression. In conclusion, our study identifies a new mechanism in which GITR ligation redirects iTregs into Th9 cells to mediate potent anti-tumor immunity. This new finding may have important clinical implications in cancer therapy.
Supplementary Figure 3 from Specific Recruitment of Γδ Regulatory T Cells in Human Breast Cancer

Jian Ye,Chunling Ma,Fang Wang,Eddy C. Hsueh,Karoly Toth,Yi Huang,Wei Mo,Shuai Liu,Bing Han,Mark A. Varvares,Daniel F. Hoft,Guangyong Peng

DOI: https://doi.org/10.1158/0008-5472.22396598.v1

2023-01-01

Abstract:PDF file, 4006K, Neutralization of IP-10 does not affect the trafficking and distribution of tumor-specific effector CD8+ TIL586 cells into tumor sites in tumor-bearing mice.
Supplementary Figure Legends from Mir-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma

Jun Wei,Fei Wang,Ling-Yuan Kong,Shuo Xu,Tiffany Doucette,Sherise D. Ferguson,Yuhui Yang,Kayla McEnery,Krishan Jethwa,Olsi Gjyshi,Wei Qiao,Nicholas B. Levine,Frederick F. Lang,Ganesh Rao,Gregory N. Fuller,George A. Calin,Amy B. Heimberger

DOI: https://doi.org/10.1158/0008-5472.22394862.v1

2023-01-01

Abstract:Supplementary Figure Legends - PDF file 70K, Supplementary Figure Legends
Supplementary Table 1 from FOXP3 Defines Regulatory T Cells in Human Tumor and Autoimmune Disease

Ilona Kryczek,Rebecca Liu,Guobin Wang,Ke Wu,Xiaogong Shu,Wojciech Szeliga,Linhua Vatan,Emily Finlayson,Emina Huang,Diane Simeone,Bruce Redman,Theodore H. Welling,Alfred Chang,Weiping Zou

DOI: https://doi.org/10.1158/0008-5472.22381422

2023-01-01

Abstract:Supplementary Table 1 from FOXP3 Defines Regulatory T Cells in Human Tumor and Autoimmune Disease
Supplementary Figure 8 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

Yanli Pang,Sudheer Kumar Gara,Bhagelu R. Achyut,Zhaoyang Li,Hannah H. Yan,Chi‐Ping Day,Jonathan M. Weiss,Giorgio Trinchieri,John C. Morris,Li Yang

DOI: https://doi.org/10.1158/2159-8290.22530045.v1

2023-01-01

Abstract:Supplementary Figure 8 - PDF file 84K, Immune cell profiling and IFN-gamma production in CD8 T cells in tumor tissues between Tgfbr2flox/flox and Tgfbr2MyeKO mice bearing 4T1 tumors
Acquisition of suppressive function by conventional T cells limits antitumor immunity upon Treg depletion

Sarah K Whiteside,Francis M Grant,Giorgia Alvisi,James Clarke,Leqi Tang,Charlotte J Imianowski,Baojie Zhang,Alexander C Evans,Alexander J Wesolowski,Alberto G Conti,Jie Yang,Sarah N Lauder,Mathew Clement,Ian R Humphreys,James Dooley,Oliver Burton,Adrian Liston,Marco Alloisio,Emanuele Voulaz,Jean Langhorne,Klaus Okkenhaug,Enrico Lugli,Rahul Roychoudhuri

DOI: https://doi.org/10.1126/sciimmunol.abo5558

2023-12-15

Abstract:Regulatory T (Treg) cells contribute to immune homeostasis but suppress immune responses to cancer. Strategies to disrupt Treg cell-mediated cancer immunosuppression have been met with limited clinical success, but the underlying mechanisms for treatment failure are poorly understood. By modeling Treg cell-targeted immunotherapy in mice, we find that CD4+ Foxp3- conventional T (Tconv) cells acquire suppressive function upon depletion of Foxp3+ Treg cells, limiting therapeutic efficacy. Foxp3- Tconv cells within tumors adopt a Treg cell-like transcriptional profile upon ablation of Treg cells and acquire the ability to suppress T cell activation and proliferation ex vivo. Suppressive activity is enriched among CD4+ Tconv cells marked by expression of C-C motif receptor 8 (CCR8), which are found in mouse and human tumors. Upon Treg cell depletion, CCR8+ Tconv cells undergo systemic and intratumoral activation and expansion, and mediate IL-10-dependent suppression of antitumor immunity. Consequently, conditional deletion of Il10 within T cells augments antitumor immunity upon Treg cell depletion in mice, and antibody blockade of IL-10 signaling synergizes with Treg cell depletion to overcome treatment resistance. These findings reveal a secondary layer of immunosuppression by Tconv cells released upon therapeutic Treg cell depletion and suggest that broader consideration of suppressive function within the T cell lineage is required for development of effective Treg cell-targeted therapies.
Blockade of Surface-Bound Tgf-Beta on Regulatory T Cells Abrogates Suppression of Effector T Cell Function in the Tumor Microenvironment

Sadna Budhu,David A. Schaer,Yongbiao Li,Ricardo Toledo-Crow,Katherine Panageas,Xia Yang,Hong Zhong,Alan N. Houghton,Samuel C. Silverstein,Taha Merghoub,Jedd D. Wolchok

DOI: https://doi.org/10.1126/scisignal.aak9702

IF: 9.517

2017-01-01

Science Signaling

Abstract:Regulatory T cells (T-regs) suppress antitumor immunity by inhibiting the killing of tumor cells by antigen-specific CD8(+) T cells. To better understand the mechanisms involved, we used ex vivo three-dimensional collagen-fibrin gel cultures of dissociated B16 melanoma tumors. This system recapitulated the in vivo suppression of antimelanoma immunity, rendering the dissociated tumor cells resistant to killing by cocultured activated, antigen-specific T cells. Immunosuppression was not observed when tumors excised from T-reg-depleted mice were cultured in this system. Experiments with neutralizing antibodies showed that blocking transforming growth factor-beta (TGF-beta) also prevented immunosuppression. Immunosuppression depended on cell-cell contact or cellular proximity because soluble factors from the collagen-fibrin gel cultures did not inhibit tumor cell killing by T cells. Moreover, intravital, two-photon microscopy showed that tumor-specific Pmel-1 effector T cells physically interacted with tumor-resident T-regs in mice. T-regs isolated from B16 tumors alone were sufficient to suppress CD8(+) T cell-mediated killing, which depended on surface-bound TGF-beta on the T-regs. Immunosuppression of CD8(+) T cells correlated with a decrease in the abundance of the cytolytic protein granzyme B and an increase in the cell surface amount of the immune checkpoint receptor programmed cell death protein 1 (PD-1). These findings suggest that contact between T-regs and antitumor T cells in the tumor microenvironment inhibits antimelanoma immunity in a TGF-beta-dependent manner and highlight potential ways to inhibit intratumoral T-regs therapeutically.
Supplementary Figure 9 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

Yanli Pang,Sudheer Kumar Gara,Bhagelu R. Achyut,Zhaoyang Li,Hannah H. Yan,Chi‐Ping Day,Jonathan M. Weiss,Giorgio Trinchieri,John C. Morris,Li Yang

DOI: https://doi.org/10.1158/2159-8290.22530042.v1

2023-01-01

Abstract:Supplementary Figure 9 - PDF file 150K, Gating strategy, sorting efficiency, and TbetaRII expression in myeloid cell subsets
GITR Subverts Foxp3+ Tregs to Boost Th9 Immunity Through Regulation of Histone Acetylation

Xiang Xiao,Xiaomin Shi,Yihui Fan,Xiaolong Zhang,Minhao Wu,Peixiang Lan,Laurie Minze,Yang-Xin Fu,Rafik M. Ghobrial,Wentao Liu,Xian Chang Li

DOI: https://doi.org/10.1038/ncomms9266

IF: 16.6

2015-01-01

Nature Communications

Abstract:Glucocorticoid-induced TNFR-related protein (GITR) is a costimulatory molecule with diverse effects on effector T cells and regulatory T cells (Tregs), but the underlying mechanism remains poorly defined. Here we demonstrate that GITR ligation subverts the induction of Foxp3(+) Tregs and directs the activated CD4(+) T cells to Th9 cells. Such GITR-mediated iTreg to Th9 induction enhances anti-tumour immunity in vivo. Mechanistically, GITR upregulates the NF-κB family member p50, which recruits histone deacetylases to the Foxp3 locus to produce a 'closed' chromatin structure. Furthermore, GITR ligation also activates STAT6, and STAT6 renders Il9 locus accessible via recruitment of histone acetyltransferase p300, and together with inhibition of Foxp3, GITR induces strong Th9 responses. Thus, Th9 cells and iTregs are developmentally linked and GITR can subvert tolerogenic conditions to boost Th9 immunity.
Supplementary Figure 1 from Specific Recruitment of Γδ Regulatory T Cells in Human Breast Cancer

Jian Ye,Chunling Ma,Fang Wang,Eddy C. Hsueh,Karoly Toth,Yi Huang,Wei Mo,Shuai Liu,Bing Han,Mark A. Varvares,Daniel F. Hoft,Guangyong Peng

DOI: https://doi.org/10.1158/0008-5472.22396604.v1

2023-01-01

Abstract:PDF file, 944K, IP-10 is the only functional chemokine inducing the migration of Treg cells.
Tumor Progression Locus 2 Inhibits Regulatory T Cell Development and Immunosuppressive Functions (LYM8P.640)

Xin Li,Nicole Acuff,Angela Peeks,Rebecca Kirkland,Kara Hardwick,Tamas Nagy,Wendy Watford

DOI: https://doi.org/10.4049/jimmunol.194.supp.201.16

2015-01-01

The Journal of Immunology

Abstract:Abstract Regulatory T cells (Tregs) are a specialized subset of immunosuppressive T cells that function to maintain peripheral tolerance. We previously demonstrated that the serine-threonine kinase, tumor progression locus 2 (Tpl2, also designated Cot/Map3k8), regulates TCR signaling and inflammatory cytokine secretion in CD4+ T cells. Herein, we demonstrate that Tpl2 is preferentially expressed by Tregs and regulates their development and functions. Tpl2-/- mice exhibited increased proportions of thymic natural Tregs (nTregs) as well as peripheral splenic Tregs, in vivo. Enhanced Treg development was due to a T cell autonomous defect, since Treg development from tpl2-/- naïve T cells cultured in vitro was similarly enhanced, and peripheral Treg proportions were also increased within the tpl2-/- donor compartment of mixed bone marrow chimeras. This defect depended upon TCR signal strength and was enhanced at low antigen concentrations. Importantly, tpl2-/- Tregs had increased expression of the immunosupressive cytokines, IL-10 and IL-35, and provided better protection than wild-type Tregs in vivo in a T cell transfer model of colitis. These results demonstrate that Tpl2 has an important physiological role in limiting Foxp3 expression, Treg development and functions. Therefore, Tpl2 inhibition could potentially be used to deviate pathological immune responses in a variety of autoimmune diseases towards a protective, tolerogenic response through preferential Treg induction.
Supplementary Figure 4 from Suppression of Tak1 Promotes Prostate Tumorigenesis

Min Wu,Lihong Shi,Adela Cimic,Lina Romero,Guangchao Sui,Cynthia J. Lees,J. Mark Cline,Darren F. Seals,Joseph S. Sirintrapun,Thomas P. McCoy,Wennuan Liu,Jin Woo Kim,Gregory A. Hawkins,Donna M. Peehl,Jianfeng Xu,Scott D. Cramer

DOI: https://doi.org/10.1158/0008-5472.22393428.v1

2023-01-01

Abstract:PDF file - 1MB, Complete lineage differentiation of shControl cells in vivo.
Abstract 2655: Unexpected role of the NuRD component, Chd4, in Foxp3+ Treg cells and its relevance to tumor immunotherapy

Wayne W. Hancock,Liqing Wang,Martina Minisini,Eros di Giorgio,Ivan Babic,Elmar Nurmemmedov

DOI: https://doi.org/10.1158/1538-7445.am2024-2655

IF: 11.2

2024-03-28

Cancer Research

Abstract:We are investigating basic questions like why do Foxp3+ T-regulatory (Treg) cells have at least 3 nuclear complexes involving Hdac1 and Hdac2 (CoREST, Sin3, NuRD), and how can the inhibitory effects of Foxp3+ Tregs on host anti-tumor immune responses be targeted therapeutically? Here, we report on the immune functions of chromodomain-helicase-DNA-binding protein 4 (Chd4), a key enzyme of the nucleosome remodeling and deacetylase complex (NuRD) complex. TCGA analysis showed increased Chd4 expression and Foxp3+ Tregs within lung tumors, leading us to assess the effects of conditional gene deletion within Foxp3+ murine Tregs. Chd4 knockout led to systemic autoimmunity and death of mice within 3 weeks of life and RNAseq studies showed Chd4 loss led to derepression of ~1400 genes and repression of >700 further genes resulting in a Treg signature markedly different from conditional deletion of Hdac1, Hdac2 or Mbd2 in Treg cells. Chd4 is an intrinsically disordered therapeutic target without a defined structure outside its physiological cell environment. To date, no specific inhibitors targeting Chd4 have been developed. We have identified Ch41, a novel and potent inhibitor of Chd4, using a novel cellular target engagement platform. Transcriptomic and mass-spec investigations showed that Ch41 impaired thymic Treg function and iTreg development, led to decreased CNS2 demethylation within the Foxp3 locus, and significantly impaired growth of lung tumors and hepatocellular carcinomas in immunocompetent but not in immunodeficient C57BL/6 mice (p<0.01). Following Chd4 inhibitor therapy, intratumoral conventional T cells had increased activation and cytokine production (IL-2, IFN-g) compared to intratumoral T cells in control tumor-bearing mice but, perhaps unexpectedly, treated mice did not show histologic or biochemical evidence of autoimmunity. We conclude that while tumor associated Tregs have unique properties that include their increased suppressive activity compared to non-tumor associated Treg cells, they are also more susceptible than the latter and conventional T cells to newly developed therapeutic interventions, including targeting of the Chd4 chromodomain of the NuRD complex. Citation Format: Wayne W. Hancock, Liqing Wang, Martina Minisini, Eros di Giorgio, Ivan Babic, Elmar Nurmemmedov. Unexpected role of the NuRD component, Chd4, in Foxp3+ Treg cells and its relevance to tumor immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2655.

oncology
Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas

Zohreh Amoozgar,Jonas Kloepper,Jun Ren,Rong En Tay,Samuel W. Kazer,Evgeny Kiner,Shanmugarajan Krishnan,Jessica M. Posada,Mitrajit Ghosh,Emilie Mamessier,Christina Wong,Gino B. Ferraro,Ana Batista,Nancy Wang,Mark Badeaux,Sylvie Roberge,Lei Xu,Peigen Huang,Alex K. Shalek,Dai Fukumura,Hye-Jung Kim,Rakesh K. Jain

DOI: https://doi.org/10.1038/s41467-021-22885-8

IF: 16.6

2021-05-11

Nature Communications

Abstract:Abstract Immune checkpoint blockers (ICBs) have failed in all phase III glioblastoma (GBM) trials. Here, we show that regulatory T (Treg) cells play a key role in GBM resistance to ICBs in experimental gliomas. Targeting glucocorticoid-induced TNFR-related receptor (GITR) in Treg cells using an agonistic antibody (αGITR) promotes CD4 Treg cell differentiation into CD4 effector T cells, alleviates Treg cell-mediated suppression of anti-tumor immune response, and induces potent anti-tumor effector cells in GBM. The reprogrammed GBM-infiltrating Treg cells express genes associated with a Th1 response signature, produce IFNγ, and acquire cytotoxic activity against GBM tumor cells while losing their suppressive function. αGITR and αPD1 antibodies increase survival benefit in three experimental GBM models, with a fraction of cohorts exhibiting complete tumor eradication and immune memory upon tumor re-challenge. Moreover, αGITR and αPD1 synergize with the standard of care treatment for newly-diagnosed GBM, enhancing the cure rates in these GBM models.

multidisciplinary sciences
Supplemental Figure 6 from CTLA-4 Limits Anti-CD20–Mediated Tumor Regression

Zhenhua Ren,Jingya Guo,Jing Liao,Yan Luan,Zhida Liu,Zhichen Sun,Xiaojuan Liu,Yong Liang,Hua Peng,Yang-Xin Fu

DOI: https://doi.org/10.1158/1078-0432.22467110.v1

2023-01-01

Abstract:Supplementary Figure 6. The percentage of CTLA4+ CD8+ T cells is much lower than that of CTLA-4+ Treg cells in the large established B-cell lymphoma.
Loss of Foxp3+ Regulatory T cell Function in Glioblastoma (P4.240)

daniel e lowther,amanda l hernandez,xiangguo duan,murat gunel,david a hafler

DOI: https://doi.org/10.1212/wnl.84.14_supplement.p4.240

IF: 9.9

2015-01-01

Neurology

Abstract:OBJECTIVE: To understand the mechanism used by glioblastomas to escape immune surveillance. BACKGROUND: The immune response in tumors is characterized by a functionally suppressed cellular infiltrate with enrichment of CD4+CD25+CD127-Foxp3+ regulatory T cells (Treg) in the tumor microenvironment. It has been thought that tumor derived Tregs possess increased regulatory function owing to the presence of the co-inhibitory receptor PD-1 on their cell surface. DESIGN/METHODS: We isolated viable infiltrating lymphocytes from freshly resected tumors with matched peripheral blood of patients with glioblastoma and determined the functional efficacy of these cell populations. RESULTS: We observed increased expression of co-inhibitory molecules PD-1 and Tim3 on the surface of both Tregs and CD4+ effector T cells infiltrating the tumor microenvironment. Tumor-derived effector cells displayed impaired proliferative responses to anti-CD3/CD28 stimulation while exhibiting robust cytokine responses. Though present in the tumor in increased numbers, tumor derived Tregs surprisingly exhibited less ex vivo suppressor function as compared to matched circulating Tregs. Investigation of PD-1+ Tregs from the circulation of healthy controls revealed a similar phenotype with loss of ex vivo suppressor function associated with IFNγ secretion. CONCLUSIONS: These data indicate that the PD-1+ infiltrating tumor derived Tregs are dysfunctional and the impaired immune response in patients with glioblastomas is related to poor T effector cell function that may be amenable to anti-PD-1 therapy. Disclosure: Dr. Lowther has received research support from Bristol-Myers Squibb. Dr. Hernandez has nothing to disclose. Dr. Duan has nothing to disclose. Dr. Gunel has nothing to disclose. Dr. Hafler has received personal compensation for activities with Genzyme, NKT Therapeutics, and Novartis as a consultant.
Supplemental Figure 1 from CTLA-4 Limits Anti-CD20–Mediated Tumor Regression

Zhenhua Ren,Jingya Guo,Jing Liao,Yan Luan,Zhida Liu,Zhichen Sun,Xiaojuan Liu,Yong Liang,Hua Peng,Yang-Xin Fu

DOI: https://doi.org/10.1158/1078-0432.22467125

2023-01-01

Abstract:Supplementary Figure 1. The therapeutic effect of anti-CD20 is not CD4+ T cell-dependent.
Supplementary Figures 1 - 3 from Reducing CD73 Expression by IL1β-Programmed Th17 Cells Improves Immunotherapeutic Control of Tumors

Shilpak Chatterjee,Krishnamurthy Thyagarajan,Pravin Kesarwani,Jin H. Song,Myroslawa Soloshchenko,Jianing Fu,Stefanie R. Bailey,Chenthamarkshan Vasu,Andrew S. Kraft,Chrystal M. Paulos,Xue-Zhong Yu,Shikhar Mehrotra

DOI: https://doi.org/10.1158/0008-5472.22403507.v1

2023-01-01

Abstract:<p>Supplementary Figure 1: Differential cytolytic potential and activation of Th17IL-1β cells in culture. Supplementary figure 2: Ectonucleotidase expression and persistence of different Th17 cells. Supplementary figure 3: Schematic summary highlighting the effect of different Th17 programming conditions on anti-tumor function.</p>
Supplementary Figure 3 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

Yanli Pang,Sudheer Kumar Gara,Bhagelu R. Achyut,Zhaoyang Li,Hannah H. Yan,Chi‐Ping Day,Jonathan M. Weiss,Giorgio Trinchieri,John C. Morris,Li Yang

DOI: https://doi.org/10.1158/2159-8290.22530060.v1

2023-01-01

Abstract:Supplementary Figure 3 - PDF file 76K, IFN-gamma production by T cells and its effect on tumor growth in Tgfbr2MyeKOand Tgfbr2flox/flox control mice

Supplementary Figure 1 from GITR Pathway Activation Abrogates Tumor Immune Suppression Through Loss of Regulatory T-cell Lineage Stability

Supplemetal Data from Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

GITR Costimulation Redirects Regulatory T Cells into Th9 Cells to Promote Antitumor Immunity (LYM8P.643)

Supplementary Figure 3 from Specific Recruitment of Γδ Regulatory T Cells in Human Breast Cancer

Supplementary Figure Legends from Mir-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma

Supplementary Table 1 from FOXP3 Defines Regulatory T Cells in Human Tumor and Autoimmune Disease

Supplementary Figure 8 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

Acquisition of suppressive function by conventional T cells limits antitumor immunity upon Treg depletion

Blockade of Surface-Bound Tgf-Beta on Regulatory T Cells Abrogates Suppression of Effector T Cell Function in the Tumor Microenvironment

Supplementary Figure 9 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

GITR Subverts Foxp3+ Tregs to Boost Th9 Immunity Through Regulation of Histone Acetylation

Supplementary Figure 1 from Specific Recruitment of Γδ Regulatory T Cells in Human Breast Cancer

Tumor Progression Locus 2 Inhibits Regulatory T Cell Development and Immunosuppressive Functions (LYM8P.640)

Supplementary Figure 4 from Suppression of Tak1 Promotes Prostate Tumorigenesis

Abstract 2655: Unexpected role of the NuRD component, Chd4, in Foxp3+ Treg cells and its relevance to tumor immunotherapy

Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas

Supplemental Figure 6 from CTLA-4 Limits Anti-CD20–Mediated Tumor Regression

Loss of Foxp3+ Regulatory T cell Function in Glioblastoma (P4.240)

Supplemental Figure 1 from CTLA-4 Limits Anti-CD20–Mediated Tumor Regression

Supplementary Figures 1 - 3 from Reducing CD73 Expression by IL1β-Programmed Th17 Cells Improves Immunotherapeutic Control of Tumors

Supplementary Figure 3 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis